Antithrombotic Strategies in Hospitalized Adults with COVID-19
Enrolling By Invitation
18 years - 99 years
All
52 participants needed
1 Location
Brief description of study
The purpose of this study is to compare the effectiveness of antithrombotic strategies for prevention of adverse
outcomes in COVID-19 positive inpatients.
Doctors use anticoagulation medicines, known as “blood thinners”, to lower the risk of blood clots forming in blood vessels (veins and arteries). The chance of blood clots in patients who are in the hospital with COVID-19 is higher than for patients who are in the hospital for other reasons, like the flu.
The purpose of this study is to compare a lower dose to a higher dose blood thinner to speed recovery and prevent blood clots in patients who are in the hospital for COVID-19.
Participants must be hospitalized at UPenn for COVID-19.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: COVID-19
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 844298
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
